Analyst Price Targets — OMER
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 8, 2026 11:05 am | Brandon Folkes | H.C. Wainwright | $40.00 | $14.09 | TheFly | Omeros price target raised to $40 from $20 at H.C. Wainwright |
| October 15, 2025 2:53 pm | — | H.C. Wainwright | $20.00 | $10.38 | TheFly | Omeros price target raised to $20 from $9 at H.C. Wainwright |
| June 27, 2025 1:35 pm | Brandon Folkes | H.C. Wainwright | $9.00 | $3.20 | TheFly | Omeros submission adds another 2026 catalyst, says H.C. Wainwright |
| December 8, 2022 8:30 am | — | UBS | $2.00 | $2.03 | Benzinga | UBS Downgrades Omeros to Neutral, Lowers Price Target to $2 |
Latest News for OMER
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for YARTEMLEA®. The J-code for YARTEMLEA (J1289) simplifies and streamlines billing and reimbursement for patients covered by U.S. government programs (e.g., Medicare) and commercial payers. The…
Omeros Corporation (NASDAQ: OMER - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have given a buy recommendation and two have given a
The average of price targets set by Wall Street analysts indicates a potential upside of 266.7% in Omeros (OMER). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
JPMorgan Chase and Co. grew its position in Omeros Corporation (NASDAQ: OMER) by 1,201.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 416,153 shares of the biopharmaceutical company's stock after buying an additional 384,168 shares during the
Medtronic (NYSE: MDT - Get Free Report) and Omeros (NASDAQ: OMER - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends. Volatility and Risk Medtronic has a beta of 0.75, suggesting
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OMER.
U.S. House Trading
No House trades found for OMER.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.